ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

On July 27, 2022 ADC Therapeutics SA (NYSE: ADCT) reported the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors (Press release, ADC Therapeutics, JUL 27, 2022, View Source [SID1234616981]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1b open-label, dose-escalation and dose-expansion clinical trial evaluates the safety and tolerability of ADCT-601 as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors. The first arm of the trial will enroll approximately 18 patients with sarcoma, a tumor resistant to current available cancer treatments in which AXL is overexpressed. For more information about the Phase 1b trial, please visit www.clinicaltrials.gov (identifier NCT05389462).

About ADCT-601

ADCT-601 is composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using GlycoConnect technology (licensed from Synaffix BV) to a linker with a pyrrolobenzodiazepine (PBD)-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based warhead. In preclinical human cancer models via AXL-mediated delivery of a PBD dimer warhead, ADCT-601 demonstrated potent and durable antitumor activity.

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

On July 27, 2022 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference, and Dr. Rice will present at the Conference (Press release, Aptose Biosciences, JUL 27, 2022, View Source [SID1234616979]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity 42nd Annual Growth Conference

Date: Wednesday, August 10, 2022
Time: 3:30 p.m. ET
Webcast: Link
The Aptose management team also will be hosting 1×1 meetings during the events.

United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022

On July 27, 2022 United Therapeutics Corporation (Nasdaq: UTHR) reported that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022 (Press release, United Therapeutics, JUL 27, 2022, View Source [SID1234616978]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United Therapeutics will host a public webcast Wednesday, August 3, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at View Source A rebroadcast of the webcast will be available for one week and can be accessed at the same location.

GEn1E Lifesciences Adds NextGen Selective Immunomodulator Target to Portfolio, Broadens Pipeline

On July 26, 2022 GEn1E Lifesciences, a next-generation multitarget techbio company developing novel and targeted immunomodulators, reported the company has secured an exclusive, worldwide, all-fields license from the University of Maryland, Baltimore (UMB) for patented next-generation Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) immunomodulators (Press release, GEn1E Lifesciences, JUL 26, 2022, View Source [SID1234656344]). The Company plans to use the newly licensed compounds to advance its portfolio of novel immunomodulators for rare and inflammatory diseases for patients with unmet needs in the areas of pulmonary, oncology and muscle degenerative diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ERK1/2 is part of the mitogen-activated protein kinase (MAPK) family, an essential signaling pathway that plays a key role in several basic cellular processes, including proliferation and differentiation. Given the ubiquity of the ERK cascade in cellular processes, it shares the pathogenesis of several pulmonary, oncology, and muscle degeneration diseases. ERK1/2’s multiple mechanisms-of-action make it an ideal platform candidate.

"Our ERK1/2 research has unlocked new approaches to selectively inhibit enzyme functions involved in disease, which is different from the current ERK1/2 inhibitors that block all enzyme functions and often result in unwanted toxicities and side effects," said Paul Shapiro, PhD, professor of pharmaceutical sciences at the University of Maryland School of Pharmacy and inventor of the technology. "Our discovery of compounds that target unique substrate binding pockets provides an opportunity to develop novel function-selective kinase therapies that will treat the disease and cause fewer side effects."

The new license builds on the strong working relationship between GEn1E and UMB. In 2019, GEn1E licensed a technology from UMB for developing next-generation p38 immunomodulators. That agreement is bearing fruit today with a lead compound in the clinic and several more novel compounds being accelerated in the pipeline.

"With the addition of ERK1/2 as a new target, the scope of diseases for which we can point our powerful AI-based ‘Platform in a Mechanism’ model expands greatly," said Ritu Lal, PhD, CEO of GEn1E. "The University of Maryland, Baltimore has produced stellar technologies that have the potential to create long-lasting impacts for patients, many of whom are devastated without effective therapies. A proud UMB alum myself, I am thrilled to continue growing a close working relationship with the University."

The power of GEn1E’s platform is evident in the progress the Company has made since graduating from Y Combinator in late 2019. The Company’s lead compound is in clinical stage and GEn1E scientists have developed more than 21 novel next-generation immunomodulators—all using only seed funding. GEn1E has demonstrated an unprecedentedly fast pace and efficiency in drug development using it’s AI platform.

"We are delighted to license additional assets to GEn1E Lifesciences and continue to develop our strong working relationship," said Phil Robilotto, DO, MBA, associate vice president of technology transfer at UMB and director of UM Ventures. "GEn1E’s application of machine learning to accelerate the process of drug development is very exciting and we are thrilled to see the unmet needs of novel and next-generation therapies being fulfilled."

BB102 Approved for Clinical Trials in Patients with Advanced Solid Tumors

On July 26, 2022 BroadenBio reported the company received the new drug clinical trial approval notice for the Class I investigational new drug BB102 from the Center of Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on July 26th, 2022 (Press release, BroadenBio, JUL 26, 2022, View Source [SID1234640199]). The first-in-human Phase 1 clinical trials for advanced solid tumors in China will be initiated soon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BB102 is an innovative small molecule kinase inhibitor discovered and being developed by BroadenBio for the treatment of advanced solid tumors driven by abnormal oncogenic genes. Besides its novel mechanism of action, high selectivity, good safety, and over advantages, BB102 shows promising efficacy to mutation-driven tumors, and is expected to benefit more cancer patients.